Liraglutide
Also known as: Saxenda, Victoza, NN2211
Liraglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes treatment that demonstrates significant weight loss effects through appetite suppression and delayed gastric emptying.
Liraglutide is a 3751.2 Da research peptide. Liraglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes treatment that demonstrates significant weight loss effects through appetite suppression and delayed gastric emptying.
Also called: Saxenda, Victoza, NN2211
3751.2
Molecular Weight
Daltons
4
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
1.2-3
Typical Dose
mg
Overview
Liraglutide functions as a synthetic analog of human glucagon-like peptide-1 (GLP-1), sharing 97% sequence homology with native GLP-1. The peptide binds to GLP-1 receptors in pancreatic beta cells, intestinal tissue, and hypothalamic regions controlling satiety. Unlike endogenous GLP-1, which has a half-life of only 1-2 minutes due to rapid DPP-4 degradation, liraglutide incorporates fatty acid modifications that enable albumin binding and extend its half-life to approximately 13 hours. This modification allows once-daily dosing while maintaining sustained GLP-1 receptor activation. The peptide's primary mechanisms include glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation through hypothalamic GLP-1 receptors. Clinical research demonstrates consistent weight loss averaging 5-10% of baseline body weight when combined with lifestyle interventions.
Key Takeaways: Liraglutide
- Strongest evidence supports Liraglutide for weight loss and glycemic control
- Research doses typically range from 1.2 to 3 mg via subcutaneous
- 4 benefits with strong evidence, 3 moderate, 0 preliminary
- Half-life: 13 hours
- 4 cited research studies in this guide
Mechanism of Action
Liraglutide activates GLP-1 receptors located in pancreatic islets, gastrointestinal tract, and central nervous system. Upon binding, the peptide triggers cAMP-dependent signaling cascades that produce glucose-dependent insulin release from pancreatic beta cells while simultaneously suppressing glucagon secretion from alpha cells. The peptide delays gastric emptying through direct action on gastric smooth muscle GLP-1 receptors, extending satiety duration. Central appetite suppression occurs via hypothalamic GLP-1 receptors in the arcuate nucleus and paraventricular nucleus, reducing food intake through decreased neuropeptide Y expression and increased POMC neuron activity.
Research Benefits
Liraglutide at a Glance
Liraglutide activates GLP-1 receptors located in pancreatic islets, gastrointestinal tract, and central nervous system.
Weight Loss
Strong EvidenceLiraglutide produces dose-dependent weight loss averaging 8-10% of baseline body weight at 3.0mg daily doses through combined appetite suppression and delayed gastric emptying mechanisms.
Glycemic Control
Strong EvidenceThe peptide reduces HbA1c levels by 0.9-1.5% in diabetic patients through glucose-dependent insulin secretion and glucagon suppression, minimizing hypoglycemia risk.
Cardiovascular Protection
Strong EvidenceLiraglutide reduces major adverse cardiovascular events by 13% in high-risk patients, likely through improved endothelial function and reduced inflammatory markers.
Appetite Suppression
Strong EvidenceCentral GLP-1 receptor activation in hypothalamic satiety centers reduces caloric intake by 15-25% through enhanced meal-related satiety signals.
Beta Cell Preservation
Moderate EvidenceThe peptide maintains pancreatic beta cell mass and function through anti-apoptotic signaling pathways and enhanced beta cell proliferation in preclinical models.
Fatty Liver Improvement
Moderate EvidenceLiraglutide reduces hepatic steatosis and liver enzyme levels, potentially through decreased lipogenesis and enhanced fatty acid oxidation.
Blood Pressure Reduction
Moderate EvidenceThe peptide produces modest systolic blood pressure reductions of 3-5 mmHg, independent of weight loss effects.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Weight management research | 1.2–3 mg | subcutaneous |
| Metabolic research | 0.6–1.8 mg | subcutaneous |
Frequency
Once daily
Timing
Any time of day, preferably consistent timing
Cycle Length
Long-term use typical in research protocols
Research Notes
- 1Begin with 0.6mg daily and increase weekly by 0.6mg increments
- 2Maximum therapeutic dose is 3.0mg daily for weight management
- 3Dose escalation reduces gastrointestinal side effects
- 4Inject in abdomen, thigh, or upper arm with site rotation
- 5Research purposes only - not for human consumption
Reconstitution Guide
Standard Reconstitution
Vial Size
3 mg
Bacteriostatic Water
1 mL
Concentration
30 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Liraglutide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 1 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 28 days after first use.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
28 days after first use
Important Notes
- •Supplied as pre-filled pen devices in clinical formulations
- •Do not freeze or shake vigorously
- •Clear, colorless solution when properly stored
- •Discard if solution appears cloudy or contains particles
- •For research applications only
Liraglutide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Liraglutide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea (most common, affects 40-50% initially)
- !Vomiting and gastrointestinal upset
- !Diarrhea or constipation
- !Abdominal pain and bloating
- !Decreased appetite extending beyond therapeutic intent
- !Injection site reactions (redness, swelling)
- !Potential pancreatitis risk (rare but serious)
- !Gallbladder complications including gallstones
- !Thyroid C-cell hyperplasia (preclinical models)
- !Hypoglycemia when combined with insulin or sulfonylureas
Potential Interactions
- ⚡Insulin and sulfonylureas (increased hypoglycemia risk)
- ⚡Oral medications requiring rapid absorption (delayed due to gastric emptying)
- ⚡Warfarin (potential INR changes requiring monitoring)
- ⚡Acetaminophen absorption may be delayed
- ⚡Digoxin levels may require monitoring due to gastric effects
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Effect of liraglutide on body weight in non-diabetic obese subjects
Randomized trial demonstrating 4.8-7.2kg weight loss with liraglutide 1.2-3.0mg daily over 20 weeks in obese non-diabetic subjects.
Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER trial showing 13% reduction in major adverse cardiovascular events with liraglutide versus placebo in 9,340 patients over 3.8 years.
Effects of liraglutide in the treatment of obesity
SCALE Obesity trial demonstrating 8.4kg average weight loss with liraglutide 3.0mg daily versus 2.8kg with placebo over 56 weeks.
Liraglutide effects on gastric emptying
Study confirming dose-dependent gastric emptying delay contributing to satiety effects and weight loss mechanisms.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Clinical trials show average weight loss of 5-10% of baseline body weight with liraglutide 3.0mg daily, typically 8-15 pounds over 6 months when combined with diet and exercise modifications.
Initial appetite suppression occurs within days, but significant weight loss typically becomes apparent after 4-6 weeks of treatment with proper dose escalation.
Nausea affects 40-50% of users initially but usually decreases with continued use. Other common effects include vomiting, diarrhea, constipation, and abdominal discomfort.
Pancreatitis is a rare but serious potential side effect. Stop use and seek medical attention for severe abdominal pain, especially if radiating to the back with nausea and vomiting.
Inject subcutaneously in abdomen, thigh, or upper arm. Rotate injection sites daily, inject at consistent times, and never share injection devices between individuals.
Liraglutide delays gastric emptying, potentially affecting oral medication absorption. It increases hypoglycemia risk when combined with insulin or sulfonylureas.
Clinical studies demonstrate safety for continuous use up to 3-4 years. Long-term effects beyond this timeframe require additional research to establish safety profiles.
Weight regain commonly occurs when discontinuing liraglutide, as the appetite suppression and metabolic effects reverse. Gradual dose reduction may help minimize rebound effects.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.